Pivotal ALCANZA Trial Secures Adcetris' Position in Cutaneous Lymphoma

Regarding FDA filing in new CTCL indication in 2017, Seattle Genetics is hoping for a label that covers all patients, regardless of positivity for CD30, though the Phase III ALCANZA study was done in biomarker expressers.